Welcome to Activiomics

Announcement 22nd November 2012

Activiomics signs research agreement with KYOWA HAKKO KIRIN (KHK) as part of its strategic partnership with BioFocus

Activiomics today announces it has signed a research agreement with the Japanese pharmaceutical company Kyowa Hakko Kirin. Under the agreement, Activiomics will apply its novel TIQUAS phosphoproteomics platform to elucidate signalling mechanisms of lead compounds in relevant cell-based systems. This agreement was signed as part of Activiomics’ recently announced strategic partnership with BioFocus.

Read the full announcement here..

About Activiomics

Activiomics has developed innovative technologies using mass spectrometry to interrogate and interpret the activity of cellular signalling pathways.

Activiomics partners with the pharmaceutical and biotechnology industry to generate high value information using its novel TIQUAS platform. This has significant advantages over existing phosphoproteomics techniques

Click here to find out more about our technology

New Vacancies

Significant commercial traction and venture capital investment with Activiomics is currently driving rapid expansion of our team. We're always looking for the best people to join us.

Click here to see our current vacancies page

Contact us for more information